Company Overview and News

 
Bud brewer hopeful that aluminum tariffs won't hit US allies - Channel NewsAsia

1h channelnewsasia
Anheuser-Busch InBev , the world's largest brewer, is hopeful that the United States will grant permanent exemptions to aluminum imported from allies and wants U.S. Congress to look into price spikes that have already set in.
Upvote Downvote

 
Bud brewer hopeful that aluminium tariffs won't hit U.S. allies

1h reuters
BRUSSELS (Reuters) - Anheuser-Busch InBev (ABI.BR), the world’s largest brewer, is hopeful that the United States will grant permanent exemptions to aluminum imported from allies and wants U.S. Congress to look into price spikes that have already set in.
Upvote Downvote

 
Play Into the Seasonal Strength of Anheuser Busch InBev NV (ADR)

22h investorplace
After giving back nearly all of its post-earnings gains on the stock market, Anheuser Busch InBev NV (ADR) (NYSE:BUD) resumed its medium-term downtrend. Markets are foolishly ignoring the seasonal strength ahead, the inroads to an improved balance sheet and the company’s strong execution on its growth plans for 2018.
Upvote Downvote

 
Alcohol High on Demand, Will These Stocks' Q1 Earnings Cheer?

2018-04-24 zacks
Alcohol is hardly ever in bad taste, especially American whiskey’s popularity among the spirit enthusiasts continues unabated. This is evident from the U.S. Alcohol market’s expansion spree owing to rising demand and improving consumer spending. Among the host of diverse spirts, craft beer seems to be hogging the limelight at the moment, courtesy of its popular fan base and convenient size production.
Upvote Downvote

 
Which Industries Are Benefitting From High Consumer Confidence?

2018-04-24 seekingalpha
Improving household finances helped lift the Bloomberg US Consumer Comfort Index to a 17-year high last week. With tobacco companies clearly being left on the sideline, we want to look at how the other US consumer-facing industries are doing. This information comes from Trendrating's trend capture model.
Upvote Downvote

 
Ball Corporation Not Quite On The Ball Yet

2018-04-23 seekingalpha
Ball Corporation’s (BLL) revenue growth over the past two years has been erratic, with much of the gains coming from its acquisition of Rexam in 2016. Debt levels are still considerably high and the cash flow forecast for 2018 leaves something to be desired. With a goal is to take free cash flow up to $1 billion by 2019 (up from $920 million in 2017), Ball has its work cut out over fiscal 2018. If synergies from the acquisition are not realized over the next few quarters in the form of improved margins, Ball’s valuation may move lower before the company regains traction in its biggest market: North and Central America.
Upvote Downvote

 
Big Read: Technology wave set to lift shipping industry

2018-04-23 nzherald.co.nz
Globalisation has brought the most advanced trading networks the world has seen, with the biggest, fastest vessels, robot-operated ports and vast computer databases tracking cargoes. But it all still relies on millions and millions of paper documents.
Upvote Downvote

 
Tune Out The Noise And Buy Altria Now

2018-04-23 seekingalpha
The company owns top-selling Marlboro brand in the U.S. market, and will grow market share with the IQOS product.
Upvote Downvote

 
Shipping Industry Has a Blockchain Problem - Bloomberg

2018-04-22 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Blockchain will speed up overseas shipping

2018-04-20 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
Upvote Downvote

 
The next mega merger could be a $60 billion drug deal

2018-04-19 money.cnn
Shares in Shire (SHPG) surged by as much as 12% on Thursday in London trading after two rival drugmakers said they were considering a bid for the biotech company.
Upvote Downvote

 
Acquisition Cycle Creates Value Opportunity With Molson Coors

2018-04-19 seekingalpha
The acquisition of Miller assets in 2016 has created what I call an acquisition cycle for Molson Coors.
Upvote Downvote

 
Blockchain Is About to Revolutionize the Shipping Industry - Bloomberg

2018-04-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Molson Coors On Tap For 35% Upside

2018-04-18 seekingalpha
As relatively hard-to-value, index-heavy Technology stocks tumble and questions about the economic growth story unfold, it may be time to add defensive positions to your portfolio.
Upvote Downvote

 
What to look for as Q1 earnings hit around the globe

2018-04-18 themalaymailonline
Johnson & Johnson says as a result of tax reform, it plans to increase spending on research and capital investment by 15 per cent over the next four years. — Reuters picNEW YORK, April 18 — Trade, taxes and China are the main themes to watch for heading into first-quarter earnings, along with a spate of potential deals.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 03524A108